clinical trial · NCT06346197
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Centre Leon Berard·phase3·recruiting·n = 132
Gastric CancerMSI-HMetastatic CancerAdvanced CancerBalstilimabBotensilimabFolfox ProtocolXELOXNivolumab
brief summary
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).
started
Dec 8, 2025
primary completion
May 15, 2028
completion
May 15, 2028
last updated
Apr 21, 2026
official title
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol